WO2004038381A3 - Procedes permettant de decouvrir des medicaments, de traiter des maladies et de poser des diagnostics a l'aide de la metabolomique - Google Patents

Procedes permettant de decouvrir des medicaments, de traiter des maladies et de poser des diagnostics a l'aide de la metabolomique Download PDF

Info

Publication number
WO2004038381A3
WO2004038381A3 PCT/US2003/034172 US0334172W WO2004038381A3 WO 2004038381 A3 WO2004038381 A3 WO 2004038381A3 US 0334172 W US0334172 W US 0334172W WO 2004038381 A3 WO2004038381 A3 WO 2004038381A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
metabolomics
diagnosis
drug discovery
disease treatment
Prior art date
Application number
PCT/US2003/034172
Other languages
English (en)
Other versions
WO2004038381A2 (fr
Inventor
Rima Kaddurah-Daouk
Original Assignee
Metabolon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolon Inc filed Critical Metabolon Inc
Priority to AU2003286726A priority Critical patent/AU2003286726A1/en
Publication of WO2004038381A2 publication Critical patent/WO2004038381A2/fr
Publication of WO2004038381A3 publication Critical patent/WO2004038381A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Selon la présente invention, on compare les profils de petites molécules pour identifier les petites molécules qui sont modulées dans les états modifiés. L'invention se rapporte également à des bibliothèques cellulaires de petites molécules, à des procédés permettant d'identifier des sources tissulaires, à des procédés permettant de traiter des maladies génétiques et non génétiques, et à des procédés permettant de prédire l'efficacité de médicaments.
PCT/US2003/034172 2002-10-25 2003-10-27 Procedes permettant de decouvrir des medicaments, de traiter des maladies et de poser des diagnostics a l'aide de la metabolomique WO2004038381A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003286726A AU2003286726A1 (en) 2002-10-25 2003-10-27 Methods for drug discovery, disease treatment, and diagnosis using metabolomics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42122602P 2002-10-25 2002-10-25
US60/421,226 2002-10-25

Publications (2)

Publication Number Publication Date
WO2004038381A2 WO2004038381A2 (fr) 2004-05-06
WO2004038381A3 true WO2004038381A3 (fr) 2004-07-01

Family

ID=32176684

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/034172 WO2004038381A2 (fr) 2002-10-25 2003-10-27 Procedes permettant de decouvrir des medicaments, de traiter des maladies et de poser des diagnostics a l'aide de la metabolomique

Country Status (2)

Country Link
AU (1) AU2003286726A1 (fr)
WO (1) WO2004038381A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2443806A1 (fr) 2000-04-14 2002-10-25 Metabolon, Inc. Procedes permettant de decouvrir des medicaments, de traiter des maladies et de poser des diagnostics a l'aide de la metabolomique
US7329489B2 (en) 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US8265877B2 (en) 2005-06-30 2012-09-11 Biocrates Life Sciences Ag Apparatus and method for analyzing a metabolite profile
WO2007050318A2 (fr) * 2005-10-24 2007-05-03 Duke University Approches lipidomiques de troubles du systeme nerveux central
US8137977B2 (en) 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
WO2007127192A2 (fr) * 2006-04-24 2007-11-08 Duke University Approches lipidomiques pour déterminer des phénotypes de réponse à un médicament dans une maladie cardiovasculaire
US8849577B2 (en) 2006-09-15 2014-09-30 Metabolon, Inc. Methods of identifying biochemical pathways
US7728287B2 (en) 2007-03-01 2010-06-01 Lawrence Livermore National Security, Llc Imaging mass spectrometer with mass tags
EP2457098B1 (fr) * 2009-07-22 2014-08-13 Eli Lilly and Company Méthode de prévision du gain de poids associé avec un traitement pharmaceutique
ES2455124T5 (es) 2010-05-05 2018-05-08 Zora Biosciences Oy Biomarcadores lipidómicos para la aterosclerosis y afección cardíaca
CN103154742B (zh) 2010-06-20 2017-11-21 佐拉生物科学公司 用于鉴定高风险冠状动脉疾病患者的脂质组学标志
EP2592423A1 (fr) 2011-11-08 2013-05-15 Zora Biosciences OY Biomarqueurs lipidomiques pour la prédiction des résultats cardiovasculaires chez des patients atteints de coronaropathie ne prenant pas un traitement par statine
EP2592422A1 (fr) 2011-11-08 2013-05-15 Zora Biosciences OY Biomarqueurs lipidomiques pour la prédiction des résultats cardiovasculaires chez des patients atteints de coronaropathie prenant un traitement par statine
US10533989B2 (en) 2012-06-26 2020-01-14 University of Pittsburgh—of the Commonwealth System of Higher Education Metabolomics in pneumonia and sepsis
WO2015157407A1 (fr) * 2014-04-08 2015-10-15 Metabolon, Inc. Profilage biochimique de petites molécules de sujets individuels pour un diagnostic de maladie et une évaluation de santé
CN113514559A (zh) * 2020-04-09 2021-10-19 四川好医生攀西药业有限责任公司 一种控制美洲大蠊乙醇提取物质量的方法
CN115015534A (zh) * 2022-06-28 2022-09-06 桂林医学院 一种罗汉果中活性物质筛选方法及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055719A2 (fr) * 2000-01-28 2001-08-02 Fal Diagnostics Kit de diagnostic permettant de detecter des niveaux de creatine
US20020009740A1 (en) * 2000-04-14 2002-01-24 Rima Kaddurah-Daouk Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US6376210B1 (en) * 1999-07-06 2002-04-23 General Atomics Methods and compositions for assaying analytes
US20020081626A1 (en) * 2000-07-06 2002-06-27 Rima Kaddurah-Daouk Methods and kits for the detection of arginine compounds
US6677160B1 (en) * 1999-09-29 2004-01-13 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376210B1 (en) * 1999-07-06 2002-04-23 General Atomics Methods and compositions for assaying analytes
US6677160B1 (en) * 1999-09-29 2004-01-13 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
WO2001055719A2 (fr) * 2000-01-28 2001-08-02 Fal Diagnostics Kit de diagnostic permettant de detecter des niveaux de creatine
US20020009740A1 (en) * 2000-04-14 2002-01-24 Rima Kaddurah-Daouk Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US20020081626A1 (en) * 2000-07-06 2002-06-27 Rima Kaddurah-Daouk Methods and kits for the detection of arginine compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRINDLE ET AL.: "Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics", NATURE MED., vol. 8, no. 12, 2002, pages 1439 - 1444, XP002975960 *
BUCHOLZ ET AL.: "Metabolomics: Quantification of intracellular metabolite dynamics", BIOMOLECULAR ENGINEERING, vol. 19, 2002, pages 5 - 15, XP004369441 *
HOLMES ET AL.: "Metabonomic characterization of genetic variations in toxicological and metabolic responses using probabilistic neural networks", CHEM. RES. TOXICOL., vol. 14, 2001, pages 182 - 191, XP002975959 *

Also Published As

Publication number Publication date
AU2003286726A1 (en) 2004-05-13
WO2004038381A2 (fr) 2004-05-06
AU2003286726A8 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
WO2001078652A3 (fr) Procedes permettant de decouvrir des medicaments, de traiter des maladies et de poser des diagnostics a l'aide de la metabolomique
WO2004038381A3 (fr) Procedes permettant de decouvrir des medicaments, de traiter des maladies et de poser des diagnostics a l'aide de la metabolomique
WO2003021261A3 (fr) Procedes pour prevoir la sensibilite a un medicament de patients atteints d'une maladie inflammatoire
WO2007137187A3 (fr) Système et procédé destinés à déterminer une intervention médicale individualisée pour une pathologie
WO2005100998A3 (fr) Marqueurs membranaires destines a etre utilises pour le diagnostic et le traitement du cancer
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
MXPA05014166A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
WO2001031007A3 (fr) Molecules d'acide nucleique derivees d'un cerveau de rat et modeles de mort cellulaire programmee
WO2006048291A3 (fr) Technologie de micro-reseaux de transcriptome et procedes d'utilisation de celle-ci
WO2004013310A3 (fr) Methodes de diminution d'expression de gene cible in vivo par introduction d'arn interferant
WO2004092405A3 (fr) Gene d'hemochromatose juvenile (hfe2a), produits d'expression et leurs utilisations
WO2003087831A3 (fr) Proteines impliquees dans le cancer du sein
WO2003082078A3 (fr) Procede et compositions pour le diagnostic et le traitement du cancer bronchopulmonaire 'non a petites cellules' au moyen de profiles d'expression genique
WO2005016227A3 (fr) Methodes et compositions pharmaceutiques servant a moduler l'activation d'heparanase et leurs utilisations
EA200801853A1 (ru) Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток
WO2005121374A3 (fr) Analyse moleculaire de follicules pileux pour des maladies
WO2004087965A3 (fr) Analyse statistique de sites de liaison de facteur regulateur de genes d'expression differentielle
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
WO2004009024A3 (fr) Modulation de l'expression de la proteine kinase c-iota
WO2002077176A3 (fr) Proteines presentant une expression aberrante dans des tumeurs microdissequees capturees au laser
WO2006122971A3 (fr) Traitement de maladies a l'aide d'un systeme d'expression regulee, ameliore
NO20051159L (no) Preparater og fremgangsmater for behandling av sykdommer som viser feilsammensetting av aggregering av protein
Buesa et al. Iadademstat shows efficacy in elderly AML patients in combination with azacitidine. ALICE trial
WO2004094610A3 (fr) Wnt utilise comme facteur pour la myogenese cardiaque
WO2005017187A3 (fr) Procedes de detection et d'identification de composes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP